Guangdong Marubi Biotechnology Co., Ltd. (SHA:603983)
China · Delayed Price · Currency is CNY 24.70
+0.11 (0.45%)
Apr 15, 2026, 3:00 PM CST
SHA:603983 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,455 | 2,968 | 2,225 | 1,730 | 1,726 |
Other Revenue | 4.7 | 2.04 | 0.66 | 1.9 | 60.68 |
| 3,459 | 2,970 | 2,226 | 1,732 | 1,787 | |
Revenue Growth (YoY) | 16.48% | 33.44% | 28.52% | -3.09% | 2.41% |
Cost of Revenue | 892.81 | 793.26 | 665.27 | 557.04 | 654.5 |
Gross Profit | 2,567 | 2,177 | 1,560 | 1,175 | 1,133 |
Selling, General & Admin | 2,217 | 1,743 | 1,307 | 957.43 | 841.66 |
Research & Development | 85.37 | 73.54 | 62.29 | 52.93 | 50.49 |
Other Operating Expenses | 32.95 | 20.47 | 17.88 | 24.1 | 23.33 |
Operating Expenses | 2,335 | 1,837 | 1,385 | 1,037 | 916.19 |
Operating Income | 231.39 | 339.26 | 175.31 | 137.59 | 216.34 |
Interest Expense | -3.28 | -9.86 | -6.63 | -3.24 | -1.02 |
Interest & Investment Income | 49.25 | 44.44 | 65.05 | 43.64 | 60.14 |
Currency Exchange Gain (Loss) | 0.04 | -0.01 | 0.02 | 0.06 | 1.74 |
Other Non Operating Income (Expenses) | -1.52 | -0.29 | -0.64 | 0.21 | -0.98 |
EBT Excluding Unusual Items | 275.87 | 373.54 | 233.12 | 178.26 | 276.22 |
Gain (Loss) on Sale of Investments | 0.43 | -0.98 | 70.98 | 5.29 | 0.61 |
Gain (Loss) on Sale of Assets | 0.12 | -0.29 | 0.45 | 0.28 | 0.42 |
Asset Writedown | - | - | - | - | -0.1 |
Other Unusual Items | 19.31 | 8.39 | 12.53 | 22.75 | 32.47 |
Pretax Income | 295.73 | 380.66 | 317.09 | 206.58 | 309.63 |
Income Tax Expense | 48.99 | 38.29 | 39.5 | 39.15 | 68.43 |
Earnings From Continuing Operations | 246.74 | 342.36 | 277.59 | 167.43 | 241.19 |
Minority Interest in Earnings | 0.5 | -0.74 | -18.17 | 6.75 | 6.73 |
Net Income | 247.24 | 341.63 | 259.42 | 174.18 | 247.92 |
Net Income to Common | 247.24 | 341.63 | 259.42 | 174.18 | 247.92 |
Net Income Growth | -27.63% | 31.69% | 48.93% | -29.74% | -46.62% |
Shares Outstanding (Basic) | 399 | 402 | 399 | 405 | 400 |
Shares Outstanding (Diluted) | 399 | 402 | 399 | 405 | 400 |
Shares Change (YoY) | -0.78% | 0.70% | -1.47% | 1.30% | -0.12% |
EPS (Basic) | 0.62 | 0.85 | 0.65 | 0.43 | 0.62 |
EPS (Diluted) | 0.62 | 0.85 | 0.65 | 0.43 | 0.62 |
EPS Growth | -27.06% | 30.77% | 51.16% | -30.64% | -46.55% |
Free Cash Flow | 68.63 | -15.85 | 83.98 | -62.47 | -124.62 |
Free Cash Flow Per Share | 0.17 | -0.04 | 0.21 | -0.15 | -0.31 |
Dividend Per Share | 0.500 | 0.750 | 0.520 | 0.250 | 0.190 |
Dividend Growth | -33.33% | 44.23% | 108.00% | 31.58% | -45.71% |
Gross Margin | 74.19% | 73.29% | 70.11% | 67.83% | 63.38% |
Operating Margin | 6.69% | 11.42% | 7.88% | 7.95% | 12.11% |
Profit Margin | 7.15% | 11.50% | 11.66% | 10.06% | 13.87% |
Free Cash Flow Margin | 1.98% | -0.53% | 3.77% | -3.61% | -6.97% |
EBITDA | 290.19 | 363.85 | 192.17 | 154.13 | 231.83 |
EBITDA Margin | 8.39% | 12.25% | 8.63% | 8.90% | 12.97% |
D&A For EBITDA | 58.8 | 24.59 | 16.86 | 16.54 | 15.49 |
EBIT | 231.39 | 339.26 | 175.31 | 137.59 | 216.34 |
EBIT Margin | 6.69% | 11.42% | 7.88% | 7.95% | 12.11% |
Effective Tax Rate | 16.56% | 10.06% | 12.46% | 18.95% | 22.10% |
Revenue as Reported | 3,459 | 2,970 | 2,226 | 1,732 | 1,787 |
Advertising Expenses | 1,721 | 1,354 | 956.67 | 656.1 | 544.22 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.